Follow us on social media

Posts Tagged ‘ME/CFS & FM Biomarkers’

Differences So Clear

differences so clear

  New Research Brings Clear Differences to Light in ME/CFS by Suzanne D. Vernon, PhD  |  BHC Research Liaison There is a great song in the musical RENT titled “Seasons of Love” in which they sing about the number of minutes in a year. As I am reviewing and writing this summary of the recent paper, “Epigenetic…

Read More

A Report of Research Progress in 2016

Research Progress

Because of the investment of many supporters – donors large and small – the Bateman Horne Center (BHC) has been able to partner with cutting-edge researchers across the globe. BHC works directly with researchers to enroll well-categorized patients into their research, providing samples with material transfer agreements in place so that we continue to learn from…

Read More

Global Report of Progress with Lucinda Bateman, M.D.

progress report

An ME/CS Progress Report Lucinda Bateman, MD, BHC Founder and Medical Director, is actively engaged in ME/CFS and FM thought leadership across the globe. In October she was on the road to take part in and advance the discussions that lead to progress. In a few short weeks she participated in: October 8th – SMCI Scientific…

Read More

What’s the Buzz – October

Whats the Buzz

Buzz – October: Each month we scour the Internet to bring you a summary of news articles, blogs and research publications we think you’ll find interesting for our What’s the Buzz post. This month, Suzanne D. Vernon, PhD, BHC Research Liaison, highlights and summarize two recent research publications for you:   The Importance of Measuring Symptoms ME/CFS is…

Read More

Simple Way to Assess Orthostatic Intolerance

10 Minute Lean Test

NASA 10 Minute Lean Test* Orthostatic intolerance (OI) is an umbrella term used to describe abnormal autonomic nervous system response to orthostatic challenge.  Orthostatic hypotension (OH), neurally mediated hypotension (NMH) [or neurogenic hypotension] and postural orthostatic tachycardia syndrome (PoTS) are terms used to describe variants of this response.  The new evidence-based IOM clinical criteria for…

Read More

What’s the Buzz – September

Buzz - January 2017

Buzz – September: Each month we scour the Internet and bring you a list of news articles, blogs and research publications we think you’ll find interesting for our What’s the Buzz post.   Occasionally, we’ll highlight and summarize a few of them for you, like this one:   Confirming a Potential ME/CFS Biomarker by Suzanne D. Vernon, PhD  |…

Read More

BHC Raises $1.08 Million, Moving to New Facility!

Were Moving

We’re Moving!  In our spring campaign we laid out an audacious goal to raise $300,000 that would allow us to move into a larger facility in order to serve more patients, expand education efforts, and increase research participation. We are thrilled to announce that we have exceeded our goal by more than 260%, raising more than…

Read More

What’s the Buzz – July

Whats the Buzz

  Buzz – July: Each month we scour the Internet and bring you a list of news articles, blogs and research publications we think you’ll find interesting for our What’s the Buzz post. Occasionally, we’ll highlight and summarize a few of them for you, like this one:   Could Difference in Gut Bacteria Help Explain ME/CFS Symptoms? Suzanne D.…

Read More

Biomarkers or Bust

Biomarkers or bust

Dr. Vernon explains why for the Bateman Horne Center, the identification of biomarkers is mission-critical… It’s Biomarkers or Bust! __________ Back in 2008 when I was advocating on the Hill and at NIH for greater research dollars for ME/CFS research I was told, “Identify biomarkers and increased research dollars will follow.”  A Catch 22 if…

Read More

$3.28 Million Awarded for ME/CFS Biomarker Study

Biomarker Study

Bateman Horne Center Leadership are Co-Investigators on this Cutting-Edge Immunogenomic Study to Quantify ME/CFS Moving Toward a Genomic CBC for ME/CFS By Suzanne D Vernon, PhD There are two major barriers to identifying ME/CFS biomarkers: 1) variation in how patients are effected, in terms of symptoms and disease progression and 2) the lack of quantitative tools…

Read More